Scholarlink

Background <p>The study aims to evaluate the effectiveness of low molecular weight heparin (LMWH) in reducing neonatal morbidity in pregnancies with early-onset fetal growth restriction (FGR).</p> Methods <p>A phase III, multicenter, triple-blind, parallel-arm randomized clinical trial conducted in two university hospitals in Spain. Singleton pregnancies with early-onset placental FGR (20 + 0–31 + 6 weeks at diagnosis) were randomized to receive bemiparin (3500 IU/0.2 mL/day) or placebo from diagnosis to delivery. The primary neonatal outcome was morbidity up to hospital discharge, assessed using the Morbidity Assessment Index for Newborns (MAIN) score. Analyses followed an intention-to-treat approach.</p> Results <p>Fifty patients were randomized (25 per arm), with 49 included in the final analysis (23 LMWH, 26 placebo). Median gestational ages at inclusion were 28.7 weeks (LMWH) and 28.4 weeks (placebo). No significant differences were observed in MAIN scores between groups (171.5 vs. 290; <i>p</i> = 0.887; adjusted median difference 139.1 [95% CI −88.4 to 319.8]). NICU stay lengths were also similar (9 vs. 6.5 days; <i>p</i> = 0.738; adjusted median difference 1.08 [95% CI −0.74 to 13.4]).</p> Conclusion <p>Prophylactic LMWH started at diagnosis of early-onset FGR does not decrease neonatal morbidity or NICU stay duration.</p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>Prophylactic LMWH started at the diagnosis of early-onset FGR does not decrease neonatal morbidity or NICU stay duration.</p> </ItemContent> <ItemContent> <p>Its design is a randomized, triple-blind clinical trial, which provides high-quality evidence.</p> </ItemContent> <ItemContent> <p>LMWH is often prescribed during pregnancy for various indications, and in the absence of effective alternatives, it is increasingly used empirically in such cases. Our findings do not support its use for reducing perinatal morbidity or NICU admission duration.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neonatal morbidity in early-onset fetal growth restriction with and without anticoagulant therapy

  • 期刊论文

  • 发表日期：

    2025年10月1日

查看全文
  • Alba González,
  • Anna Peguero,
  • Eva Meler,
  • Marta Camprubi,
  • Carlota Rovira,
  • Maria Dolores Gomez-Roig,
  • Daniel Oros,
  • Patricia Ibáñez,
  • Jon Schoorlemmer,
  • Narcís Masoller,
  • Judit Hidalgo,
  • Dolores Tàssies,
  • Francesc Figueras,
  • Edurne Mazarico

摘要

Background

The study aims to evaluate the effectiveness of low molecular weight heparin (LMWH) in reducing neonatal morbidity in pregnancies with early-onset fetal growth restriction (FGR).

Methods

A phase III, multicenter, triple-blind, parallel-arm randomized clinical trial conducted in two university hospitals in Spain. Singleton pregnancies with early-onset placental FGR (20 + 0–31 + 6 weeks at diagnosis) were randomized to receive bemiparin (3500 IU/0.2 mL/day) or placebo from diagnosis to delivery. The primary neonatal outcome was morbidity up to hospital discharge, assessed using the Morbidity Assessment Index for Newborns (MAIN) score. Analyses followed an intention-to-treat approach.

Results

Fifty patients were randomized (25 per arm), with 49 included in the final analysis (23 LMWH, 26 placebo). Median gestational ages at inclusion were 28.7 weeks (LMWH) and 28.4 weeks (placebo). No significant differences were observed in MAIN scores between groups (171.5 vs. 290; p = 0.887; adjusted median difference 139.1 [95% CI −88.4 to 319.8]). NICU stay lengths were also similar (9 vs. 6.5 days; p = 0.738; adjusted median difference 1.08 [95% CI −0.74 to 13.4]).

Conclusion

Prophylactic LMWH started at diagnosis of early-onset FGR does not decrease neonatal morbidity or NICU stay duration.

Impact

Prophylactic LMWH started at the diagnosis of early-onset FGR does not decrease neonatal morbidity or NICU stay duration.

Its design is a randomized, triple-blind clinical trial, which provides high-quality evidence.

LMWH is often prescribed during pregnancy for various indications, and in the absence of effective alternatives, it is increasingly used empirically in such cases. Our findings do not support its use for reducing perinatal morbidity or NICU admission duration.